Repligen logo

Repligen

RGEN | NASDAQ
Chart Builder DCF Calculator
$162.78
-$5.01 (-2.99%)
At close: Nov 16, 2026, 4:00 PM ET
$162.78
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.99%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
42.9
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #447/1021 (Top 44%)

Key Statistics

Market Data

Market Cap $10.41B
1D Range
162.48 166.79
52W Range
102.87 194.57

Valuation (TTM)

PE -775.14
PB 4.97
EV/EBITDA 81.31

Valuation (NTM)

Forward PE 81.06
Forward PEG -32.46
Price Target $200.00
Loading financial charts...

Profile

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug product...

Sector Healthcare
Employees 2,000
IPO Date Apr 29, 1986
Fiscal Year January - December

Latest News

12 days ago · fool.com

Repligen: 3 Key Takeaways for Long-Term Investors
Repligen Corporation to Present at Jefferies Global Healthcare Conference

13 days ago · globenewswire.com

Repligen Corporation to Present at Jefferies Global Healthcare Conference
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction

18 days ago · globenewswire.com

Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

20 days ago · seekingalpha.com

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
What Repligen (RGEN) Said on Its Q3 Earnings Call

21 days ago · marketbeat.com

What Repligen (RGEN) Said on Its Q3 Earnings Call
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates

21 days ago · zacks.com

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

21 days ago · globenewswire.com

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen: A Buy As Its Growth Engine Gears Up

1 month ago · seekingalpha.com

Repligen: A Buy As Its Growth Engine Gears Up
Repligen to Report Third Quarter 2026 Financial Results

1 month ago · globenewswire.com

Repligen to Report Third Quarter 2026 Financial Results
Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tells Investors

1 month ago · gurufocus.com

Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tells Investors

Earnings

Latest Earnings
Oct 27, 2026
EPS
$0.53
Beat +14.52%
REV
$209.31M
Beat +1.26%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
10
Consensus
Buy
Price Target
$200.00
Upside
+22.87%
Buy (9)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.